Deutsch
English
Русский

Institut für Klinische Transfusionsmedizin und Hämotherapie
Oberdürrbacher Str. 6
97080 Würzburg
transfusionsmedizin@ukw.de

Direktor
Prof. Dr. med. Markus Böck
Universitätsklinikum Würzburg
Oberdürrbacher Straße 6
97080 Würzburg
Tel.: 09 31-201 313 00
Fax: 09 31-201 313 76
boeck_m@ukw.de

PUBLIKATIONEN

Publikationen

mit Beteiligung von Mitarbeitern des Instituts

Lapa C, Grigoleit GU, Hänscheid H, Klinker E, Jung P, Schirbel A, Böck M, Buck AK, Pelzer T
Peptide Receptor Radionuclide Therapy for Sarcoidosis (letter)
Am J Respir  Crit Care Med. 2016; 194(11):1428-11430

Koessler J, Etzel J, Weber K, Boeck M, Kobsar A.
Evaluation of dose-dependent effects of the proteasome inhibitor bortezomib in human platelets
European Journal of Pharmacology 2016; 791: 99-104

Schneider-Gold C, Krenzer M, Klinker E, Mansouri-Thalegani B, Müllges W, Toyka K, Gold R.
Immunadsorption versus plasma exchange versus combination for treatment of myasthenic deterioration
Ther Adv Neurol Disord 2016; 9(4): 297-303

Koessler J, Weber K, Koessler A, Yilmaz P, Boeck M, Kobsar A
Expression and function of purinergic receptors in platelets from apheresis-derived platelet concentrates 
Blood Transfus 2016;14:545-551 

Koessler J, Kobsar A, Kuhn S, Koessler A, Yilmaz P, Weinig E, Putz E, Boeck M, Klinker E.
The effect of immunoadsorption with the Immusorba TR-350 column on coagulation compared to plasma exchange.
Vox Sanguinis 2015;108(1):46-51

Lutz M, Worschech A, Alb M, Gahn S, Berhard L, Schwab M, Obermeier S, Einsele H, Kämmerer U, Heuschmann P, Klinker E, Otto C, Mielke S.
Boost and loss of immune responses against tumor-associatet antigens in the course of pregnancy as a model for allogeneic immunotherapy.
Blood 2015;125(2):261-272

Nerreter T, Köchel C, Jesper D, Eichelbrönner I, Putz E, Einsele H, Seggewiss-Berhardt R.
Dasatinib enhances migration of monocyte-derived dendritic cells by reducing phosphorylation of inhibitory immune receptors Siglec-9 an Siglec-3.
Experimental Hematology 2014;42:773-782

Kobsar A, Simonis S, Klinker E, Koessler A, Kuhn S, Boeck M, Koessler J.
Specific inhibitory effects of the NO donor MAHMA/NONOate on human platelets.
Eur J Pharmacol 2014;735:169-176

Gundermann S, Klinker E, Kimmel B, Flierl U, Wilhelm M, Einsele H, Kunzmann V.
A comprehensive analysis of primary acute myeloid leukemia identifies biomarkers predicting susceptibility to human allogeneic V¥9Vð2 T Cells.
J Immunother 2014;37:321-330

Chuang WY, Ströbel P, Bohlender-Willke AL, Rieckmann P, Nix W, Schalke B, Gold R, Opitz A, Klinker E, Inoue M, Müller-Hermelink HK, Saruhan-Direskeneli G, Bugert P, Willcox N, Marx A.
Late-onset myasthenia gravis - CTLA4(low) genotype association and low-for-age thymic output on naive T cells
Journal of Autoimmunity 2014;52:122-129

Salama A, Janvier D, Mayer B, Saison C, Moscatelli H, Aucouturier F, Yilmaz P, Arnaud L, Wild V, Knop S, Cartron JP.
Lethal autoimmune hemagglutination due to an immunoglobulin A autoagglutinin with Band 3 specificity
Transfusion 2014; 54:1988-1995

Kobsar A, Putz E, Yilmaz P, Weinig E, Boeck M, Koessler J.
Decreasing phosphodiesterase 5A activity contributes to platelet cGMP accumulation during storage of apheresis-derived platelet concentrates
Transfusion 2014;54:1008-1014

Kobsar A, Klinker E, Kuhn S, Koessler A, Yilmaz P, Boeck M, Koessler J.
Increasing susceptibility of nitric oxide-mediated inhibitory platelet signaling during storage of apheresis-derived platelet concentrates.
Transfusion 2014;54:1782-1789

Winkler B, Kuhn S, Kunzmann S, Ruf K, Wiegering V, Schlegel P-G;
Severe Hypertriglyceridemia in a 6 Year Old Boy with ALL Relapse: Successfully Treated with Plasmapheresis
Klin Padiatr 2013;225:364-365

Böck M., Klinker E.
Transfusion von Thrombozytenkonzentraten - Was ist wichtig?
DBI 2012; 5:32-38

Müller PA, Bröcker EB, Klinker E, Stoevesandt J, Benoit S.
Adjuvant Treatment of Recalcitrant Bullous Pemphigoid with Immunoadsorption.
Dermatology 2012;224:224-227

Fischer K. R. Opitz A., Böck M., Geerling G.
Stability of Serum Eye Drops After Storage of 6 Months
Cornea 2012; 11:1313-1318

Kapp M, Stevanovic S, Fick K, Tan SM, Loeffler J, Opitz A, Tonn T, Stuhler G, Einsele H, Grigoleit GU.
CD8+ T-cell responses to tumor-associated antigens correlate with superior relapse-free survival after allo-SCT
Bone Marrow Transplantation 2009; 1-12

Chuang WY, Ströbel P, Belharazem D, Rieckmann P, Toyka KV, Nix W, Schalke B, Gold R, Kiefer R, Klinker E, Opitz A, Inoue M, Kuo T, Müller-Hermelink HK, Marx A.
The PTPN22 + 1858T(+) genotypes correlate with low IL-2 expression in thymomas and predispose to myasthenia gravis
Genes and Immunity 2009;10:667-672

Schöttker B, Feuchtinger T, Schumm M, Klinker E, Handgretinger R, Einsele H, Stuhler G.
Five donors-one recipient:modeling a mosaic of granulocytes, naturel killer and T cells from cord-blood and third-party donors
Nature Clinical Practice Oncology 2008;5:291-295

Kobsar A, Heeg S, Krohne K, Opitz A, Walter U, Böck M, Gambaryah S,
Eigenthaler M.
Cyclic Nucleotide-Regulated Proliferation and Differentiation Vary in Human Hematopoietic Program. Derived from Healthy Persons, Tumor Patients, and Chronic Myelocytic Leukemia Patients
Stem Cells and Development 2008; 17(1):81-92

Zillikens D, Derfler K, Eming R, Fierlbeck G, Goebeler M, Hertl M, Hofmann S, Karlhofer F, Kautz O, Nitschke M, Opitz A, Quist S, Rose C, Schanz S, Schmidt E, Shimanovich I, Sticherling M, Ziller F.
Empfehlungen für die Anwendung der Immunapherese bei der Therapie bullöser Autoimmundermatosen
Recommendations for the use of immunoapheresis in the treatment of autoimmune bullous diseases
JDDG 2007;(10):881-888

Delleeuw R J, Zettl A, Klinker E, Haralambieva E, Trottier M, Chari R, Ge Y, Gascoyne R D, Chott A, Müller-Hermelink H-K, Lam W L.
Whole-Genome Analysis and HLA Genotyping of Enteropathy-Type T-Cell Lymphoma Reveals 2 Distinct Lymphoma Subtypes
Gastroenterology. 2007 May;132(5):1902-11 17484883

Gronen F, Ruprecht K, Weissbrich B, Klinker E, Kroner A, Hofstetter H H, Rieckmann P.
Frequency analysis of HLA-B7-restricted Epstein-Barr virus-specific cytotoxic T lymphocytes in patients with multiple sclerosis and healthy controls
J Neuroimmunol. 2006 Oct 3; : 17023054

I. Shimanovich, S. Herzog, E. Schmidt, A. Opitz, E. Klinker, E-B, Bröcker, M. Goebeler and D. Zillikens
Improved protocol for treatment of pemphigus vulgaris with protein A immunoadsorption
Clin Exp Dermatol 2006 Jul. 4:16824051

Bueter M, Thalheimer A, Schuster F, Böck M, von Erffa C, Meyer D, Fein M.
Transfusion-related acute lung injury (TRALI)-an important, severe transfusion-related complication.
Langenbecks Arch Surg. 2006 Sep;391(5):489-94

Böck M,
Novellierung des Transfusionsgesetzes: Konsequenzen für die praktische Arbeit
Bay. Ärzteblatt 5;2005;390-392

Otto K, Andersen M H, Eggert A, Keikavoussi P, Ostergaard L, Böck M, Rath J.C, Bröcker E B, Per thor Straten, Kämpgen E, Becker JC
Lack of toxicity of therapy-induced T cell responses against the universal tumour antigen survivin
Vaccine 23 (2005) 884-889

Chuang W Y, Ströbel P, Gold R, Nix W, Schalke B, Kiefer R, Opitz A, Klinker E, Müller-Hermelink H-K, Marx A.
A CTLA4high genotype is associated with myasthenia gravis in thymoma patients
Ann Neurol. 2005 Oct;58(4):644-8 16178018

Herrero-González J E, Sitaru C, Klinker E, Bröcker E B, Zillikens D.
Successful adjuvant treatment of severe bullous pemphgoid by tryptophan immunoadsorption
Clin Exp Dermatol. 2005 Sep;30(5):519-22 16045683

Ruprecht K, Klinker E, Dintelmann T, Rieckmann P, Gold R.
Plasma exchange for severe optic neuritis: treatment of 10 patients
Neurology. 2004 Sep 28;(6):1081-3 15452303

Böck M,
BSE-Übertragung durch Blutkonserven doch möglich?
Bay. Ärzteblatt 10;2004;629-630

Seeberger H, Knorr C, Mainhardt C, Müller-Hermelink HK, Greiner A.
Tumor-infiltrating T cells with similar antigen binding sites in different mucosa-associated lymphoid tissue type B cell lymphomas.
Virchows Arch 2003; 442: 343-348

Schmidt E, Klinker E, Opitz A, Herzog S, Sitaru C, Goebeler M, Mansouri B Taleghoni, Bröcker E-B, Zillikens D.
Protein A immunoadsorption: a novel and effective adjuvant treatment of severe pemphigus
British Journal of Dermatology 2003; 148; 1222-1229

Böck M, Rahrig S, Kunz D, Lutze G, Heim M U.
Platelet concentrates derived from buffy coat and apheresis: biochemical and functional differences
Transfusion Medicine 2002; 12; 317-324

Böck M, Kroker M.
Transfusion von Blutprodukten
Bayerisches Ärzteblatt 10;2001; 466-471

Bürger T, Tautenhahn J, Böck M, Fahlke J, Halloul Z, Lippert H.
Can a coated Dacron vascular graft maintain a heparin-induced thrombocytopenia type II?
Langenbeck´s Arch Surg 2001; 386:267-271

Mansouri Taleghani B, Langer R, Grossmann R, Opitz A, Halbsguth U, Buchheister A, Schuler S, Bachthaler R, Wiebecke D.
Verbesserung der biochemischen un rheologischen Qualität von Vollblut und Erythrozytenkonzentraten durch Leukozytendepletion vor Lagerung
AINS 36, 2001; Suppl. 1, S11-19

Mahlfeld K, Böck M, Franke J, Meinecke I, Schaeper O, Kayser R, Graßhoff H.
Beitrag zur Bedeutung und Inzidenz der Heparininduzierten Thrombozytopenie (HIT) Typ II.
Zentralbl Chir 126; 2001; 39-43

Grossmann R, Taleghani BM, Rader C, Kramer C, Eulert J, Keller F.
Is there any influence of the protein C system on perioperative blood loss in knee or hip arthroplasty?
Thromb Res. 2000; 99(5): 473-5

Mansouri Taleghani B, Grossmann R, Reith HB, Wiebecke D, Thiede A.
Measures for allogeneic blood conservation in surgery.
Zentralbl Chir. 2000; 125(2): 111-22

Böck M, DeHaan J, Beck KH, Gutensohn K, Hertfelder HJ, Karger R, Heim MU, Beeser H, Weber D, Kretschmer V.
Standadization of the PFA 100 platelet function test in 105 mmol/l buffered citrate: effect of gender, smoking and oral contraceptives.
Br J Haematol 106; 1999; 898-904

Greinacher A, Luz M, Janssens U, Berg G, Böck M, Kwasny H, Kempkes-Matthes B, Eichler P, Völpel H, Pötzsch B.
Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia.
Circulation 100; 1999; 587-593

Matthies B, Bürger T, Koch B, Böck M.
Die Heparin-induzierte Thrombozytopenie Typ II: Reexposition mit Heparin.
DMW 124/43; 1999; 1267-1270

Taleghani BM, Reith HB, Wiebecke D, Thiede A.
Hemotherapy in operative medicine.
Zentralbl Chir. 1999; 124(4): W27-41

Taleghani BM, Reith HB, Wiebecke D, Thiede A.
Hemotherapy in operative medicine. Part 1.
Zentralbl Chir. 1999; 124(3): W19-26

Ullrich H, Mansouri-Taleghani B, Lackner KJ, Schalke B, Bogdahn U, Schmitz G.
Chronic inflammatory demyelinating polyradiculoneuropathy: superiority of protein A immunoadsorption over plasma exchange treatment.
Transfus Sci 1998; 19: Suppl 33-8

Flachenecker P, Taleghani BM, Gold R, Grossmann R, Wiebecke D, Toyka KV.
Treatment of severe myasthenia gravis with protein A immunoadsorption cyclophosphamide.
Transfus Sci. 1998; 19: Suppl 43-6

Taleghani BM, Grossmann R, Keller F, Wiebecke D.
Therapy of coagulation factor VIII autoantibodies with long-term extracorporal protein A adsorption and immunosuppression.
Transfus Sci. 1998; 19: Suppl 39-42

Langer R, Gross D, Mansouri Taleghani B, Wiebecke D, Henrich HA.
Therapeutic thrombocytapheresis - effect on hemorheologic parameters.
Beitr Infusionsther Transfusionsmed. 1997; 34: 265-72

Mansouri Taleghani B, Manke F, Langer R, Henrich HA, Grossmann R, Hofmann R, Wiebecke D.
Changes in blood rheology and microcirculation after preparatory combination of thrombocytapheresis and plasmapheresis.
Beitr Infusionsther Transfusionsmed. 1997; 34: 123-7

Mansouri Taleghani B, Grossman R, Waltenberger G, Geise W, Langer R, Henrich HA, Wiebecke D.
Storage- induced rheologic and biochemical changes in erythrocyte conce with added solution and possible correlations.
Beitr Infusionsther Transfusionsmed. 1996; 33: 141-4

Karch H, Huppertz HI, Bohme M, Schmidt H, Wiebecke D, Schwarzkopf A.
Demonstration of Borrelia burgdorferi DNA in urine samples from health humans whose sera contain B. burgdorferi-specific antibodies.
J Clin Microbiol. 1994; 32(9): 2312-4

Ullrich H.
Donor plasmapheresis.
Klin. Anasthesiol Intensivther 1993; 45: 164-8

Eigenthaler M, Ullrich H, Geiger J, Horstrup K, Honig-Liedl P, Wiebecke D, Walter U.
Defective nitrovasodilator-stimulated protein phosphorylation and calcium regulation in cGMP-dependent protein kinase-deficient human platelets of chronic myelocytic leukemia.
J Biol Chem. 1993; 268(18): 13526-31

Wiebecke D.
The therapy of hematologic-oncologic emergencies.
Klin Anasthesiol Intensivther. 1993; 45: 206-10

Bohme M, Schwenecke S, Fuchs E, Wiebecke D, Karch H.
Screening of blood donors and recipients for Borrelia burgdorferi antibodi evidence of B. burgdorferi infection transmitted by transfusion.
Infusionsther Transfusionsmed. 1992; 19(4): 204-7

Bohme M, Schembra J, Bocklage H, Schwenecke S, Fuchs E, Karch H, Wiebecke D.
Infections with Borrelia burgdorferi in Wuerzburg blood donors: antibody prevalence, clinical aspects and pathogen detection in antibody positive donors.
Beitr Infusionsther. 1992;30:96-9

Waxenberger Y, Schad S, Gross D, Ulrich H, Hohe R, Langer R, Henrich H, Wiebecke D.
Rheologic studies before and after therapeutic cytapheresis and plasma exchange treatment.
Beitr Infusionsther 1992; 30: 301-5

Ullrich H, Kadar J, Waxenberger Y, Hohe R, Saueressig C, Heyder M, Wiebecke D.
Therapeutic thrombocytapheresis in patients with myeloproliferative disease with the cell separators Fresenius AS 104 and Cobe Spectra: biocompatibility and safety.
Beitr Infusionsther. 1992; 30: 311-4

Ullrich H, Wiebecke D, Keller F.
Side effects and risk factors of various plasma donation methods.
Beitr Infusionsther. 1991; 28: 77-81

Wiebecke D, Gunzer U, Ullrich H, Kadar J.
Therapeutic cytapheresis.
Beitr Infusionsther. 1991; 28: 226-32

Hammerl M, Wiebecke D.
Oxygen transport function, biochemical changes and 24-hour posttransfusion survival rate of erythrocytes stored in PAGGS-sorbit solution in relation to various storage conditions.
Beitr Infusionsther. 1988; 21: 53-9.

Eichler H, Gunzer U, Mingers A, Ullrich H, Wiebecke D, Zippelius E.
Comparative studies of collecting fresh plasma (FFP) using various plasmapheresis methods.
Beitr Infusionsther. 1988; 21: 122-6.

Ullrich H, Wiebecke D, Hohe R, Gunzer U, Mansouri-Taleghani B.
Complications in therapeutic cytapheresis and plasma exchange treatment
Beitr Infusionther Klin Ernahr. 1987; 18: 241-3

Reuther P, Wiebecke D, Rohkamm R, Mertens HG.
Plasma exchange treatment in neurologic diseases.
Nervenarzt 1983; 54(4): 167-70.

Struppler A, Taleghani BM.
Structure and function of the neuromuscular synapse
Klin Anasthesiol Intensivther. 1980; 22: 10-32.

Reuther P, Wiebecke D, Hertel G, Boske A, Mertens HG.
Treatment of myasthenia gravis with plasmapheresis.
Dtsch Med Wochenschr. 1979; 104(51): 1806-10

Wiebecke D.
Preparation and administration of a blood transfusion.
Schwest Rev. 1979; 17(9): 19-21

Franzen C, Brodersen M, Frosner G, Stroder J, Wiebecke D.
Hepatitis types A, B, and non A-non B in childhood.
Eur J Pediatr. 1979; 132(4): 261-9.

Eyrich K, Braun-Heine A, Sefrin P, Wiebecke D.
Clinical aspects of massive transfusion.
Infusionsther Klin Ernähr. 1978; 5(6): 340-4

Wiebecke D.
Polymorphism of human erythrocytic esterase deficiency.
Blut 1976; 33(5): 329-31

Wiebecke D.
Gene frequencies of red cell adenylate kinase and adenosine deaminase population of Northern Bavaria.
Klin Wochenschr. 1976; 54(16): 793-4

Sittner G, Wiebecke D, Trenkel K.
Experimental studies on population genetics of complement 3 (C3) and component transferin (Tf) in the population of Northern Bavaria.
Blut 1976; 32(6): 447-50

Wiebecke D.
On the occurrence and formation of human SNagg-type antigamma globulin with anti-Gm- and anti-INV-specificity.
Klin Wochenschr.1974; 52(18): 871-3

Wiebecke D.
Antigammaglobulins of human origin (editorial).
Klin Wochenschr. 1974; 52(18): 851-6

Wiebecke D, Brackebusch HD.
Studies on the polymorphism of the red cell acid phospatase in the population of Northern Bavaria (Germany).
Humangenetik 1974; 23(3): 230-2

Wiebecke D.
Studies on human antiglobulins. Some properties of a "new" type.
Vox Sang. 1974; 26(1): 86-90

Wiebecke D. Brackebusch HD.
Studies on the polymorphism of the soluble glutamic-pyruvic-transamin population of Northern Bavaria (Germany).
Humangenetik 1974; 23(3): 227-9

Wiebecke D.
Possible solutions to the problems of pressure transfusion (infusion) from bottles.
Infusionstherapie. 1973; 1(1): 58-61

Wiebecke D.
The incidence of Gm(1,2,3,5) and Inv(1) in the population of the Federal Republic of Germany.
Humangenetik 1973; 18(2): 175-80

Schellong G, Baltzer G, Gerlach U, Kommerell B, Matthes M, Wiebecke D.
Podium discussion. 14th meeting of the German Blood Transfusion Society in Giessen, 1970.
Bibl Haematol. 1971; 37: 252-63

Wiebecke D.
A simple filter device to avoid contamination of preserved blood and a pump for pressure transfusion from bottles.
Anaesthesist 1969; 18(2): 56-8

Wiebecke D.
A simple device to avoid air embolism during pressure transfusions and infusions from bottles.
Anaesthesist 1969; 18(1): 21-3

Wiebecke D, Dickhauser K, Goecke C.
The frequency of gamma globulin serum groups Gm (1,2,4,12) and Inv (1) in normal persons and in patients with carcinoma.
Bibl Haematol. 1969; 32: 64-5

Wiebecke D, Kolokythas A.
Treatment and development of two hemolytic transfusion reactions caused byAB0 incompatible blood
Münch Med Wochenschr. 1968; 110(46): 2702-6

Wiebecke D, Blennemann H.
On the occurrence and formation of specific antigamma globulins in children of different age groups. Studies of the Steinberg-Speiser phenomenon.
Wien Med Wochenschr. 1968; 118(41): 859-63

Wiebecke D, Spielmann W, Seidl S.
The frequencies of Gm(1),Gm(2), Gm(4),Gm(12), and Inv(1) in Hessen (Germany).
Humangenetik 1968; 5(3): 211-5

Wiebecke D, Spielmann W, Seidl S, Mohs S.
Contribution to population genetics of the Gm and Inv systems.
Klin Wochenschr. 1967; 45(14): 736-7


 


Grüne Schrift:
Mitarbeiter des Instituts für Klinische Transfusionsmedizin und Hämotherapie

Virchows Arch 2003;442;343-348.